Skip to main content
Journal cover image

Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.

Publication ,  Journal Article
Théroux, P; Armstrong, PW; Mahaffey, KW; Hochman, JS; Malloy, KJ; Rollins, S; Nicolau, JC; Lavoie, J; Luong, TM; Burchenal, J; Granger, CB
Published in: Eur Heart J
October 2005

AIMS: Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without apparent reductions in infarct size. Inflammation is a critical component of ST-elevation myocardial infarction (STEMI); this substudy examines prognostic values of selected markers and treatment effects. METHODS AND RESULTS: C-reactive protein, interleukin-6 (IL-6), and tumour necrosis factor-alpha (TNF-alpha) serum levels were assessed in 337 patients enrolled in either the placebo or the pexelizumab 24 h infusion group. Higher C-reactive protein and IL-6 levels at baseline, 24 h, and 72 h were strongly associated with increased subsequent death (P<0.002 at baseline and 24 h, P<0.02 at 72 h); and all baseline marker levels with death or cardiogenic shock (P<0.03) within 90 days. C-reactive protein and IL-6 levels were similar at baseline, but significantly lower 24 h later with pexelizumab, when compared with placebo (17.1 vs. 25.5 mg/L, P=0.03 and 51.0 vs. 63.8 pg/mL, P=0.04, respectively). At 72 h, corresponding levels were similar, whereas TNF-alpha was slightly higher (P=0.04) in the treated group. CONCLUSION: Inflammation markers and their serial changes predict death and shock in patients with STEMI undergoing primary angioplasty. Pexelizumab reduced C-reactive protein and IL-6, suggesting treatment benefits mediated through anti-inflammatory effects.

Duke Scholars

Published In

Eur Heart J

DOI

ISSN

0195-668X

Publication Date

October 2005

Volume

26

Issue

19

Start / End Page

1964 / 1970

Location

England

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Treatment Outcome
  • Single-Chain Antibodies
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Interleukin-6
  • Humans
  • Female
  • Enzyme-Linked Immunosorbent Assay
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Théroux, P., Armstrong, P. W., Mahaffey, K. W., Hochman, J. S., Malloy, K. J., Rollins, S., … Granger, C. B. (2005). Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J, 26(19), 1964–1970. https://doi.org/10.1093/eurheartj/ehi292
Théroux, Pierre, Paul W. Armstrong, Kenneth W. Mahaffey, Judith S. Hochman, Kevin J. Malloy, Scott Rollins, Jose C. Nicolau, et al. “Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial.Eur Heart J 26, no. 19 (October 2005): 1964–70. https://doi.org/10.1093/eurheartj/ehi292.
Théroux P, Armstrong PW, Mahaffey KW, Hochman JS, Malloy KJ, Rollins S, Nicolau JC, Lavoie J, Luong TM, Burchenal J, Granger CB. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J. 2005 Oct;26(19):1964–1970.
Journal cover image

Published In

Eur Heart J

DOI

ISSN

0195-668X

Publication Date

October 2005

Volume

26

Issue

19

Start / End Page

1964 / 1970

Location

England

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Treatment Outcome
  • Single-Chain Antibodies
  • Myocardial Infarction
  • Middle Aged
  • Male
  • Interleukin-6
  • Humans
  • Female
  • Enzyme-Linked Immunosorbent Assay